A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety, Pharmacokinetic and Pharmacodynamic Study of Orally Administered AG-348 in Healthy Volunteers

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety, Pharmacokinetic and Pharmacodynamic Study of Orally Administered AG-348 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs AG 348 (Primary)
  • Indications Haemolytic anaemia; Inborn error metabolic disorders
  • Focus Adverse reactions
  • Acronyms AG-348-SAD; SAD
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 08 Dec 2015 Results of population pharmacokinetics presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 21 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Apr 2014 Agios Pharmaceuticals announced dose administration of AG 348 for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top